Microba Life Sciences Ltd - Asset Resilience Ratio
Microba Life Sciences Ltd (MAP) has an Asset Resilience Ratio of 11.53% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Microba Life Sciences Ltd short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2024)
This chart shows how Microba Life Sciences Ltd's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see MAP total asset value.
Liquid Assets Composition Over Time
This chart breaks down Microba Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Microba Life Sciences Ltd (MAP) total liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$5.00 Million | 11.53% |
| Short-term Investments | AU$0.00 | 0% |
| Total Liquid Assets | AU$5.00 Million | 11.53% |
Asset Resilience Insights
- Moderate Liquidity: Microba Life Sciences Ltd has 11.53% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Microba Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Microba Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Veracyte Inc
NASDAQ:VCYT |
Diagnostics & Research | 12.49% |
|
Zhejiang DiAn Diagnostics Co
SHE:300244 |
Diagnostics & Research | 3.61% |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193 |
Diagnostics & Research | 70.50% |
|
Monash Ivf Group Ltd
AU:MVF |
Diagnostics & Research | 1.60% |
|
Eurofins-Cerep SA
PA:ALECR |
Diagnostics & Research | 13.42% |
|
DIVA Laboratories Ltd
TWO:4153 |
Diagnostics & Research | 0.01% |
|
RHYTHM Biosciences Ltd
AU:RHY |
Diagnostics & Research | 2.74% |
|
Imagion Biosystems Ltd
AU:IBX |
Diagnostics & Research | 150.16% |
Annual Asset Resilience Ratio for Microba Life Sciences Ltd (2018–2024)
The table below shows the annual Asset Resilience Ratio data for Microba Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 6.02% | AU$2.85 Million ≈ $2.02 Million |
AU$47.44 Million ≈ $33.56 Million |
-1.60pp |
| 2023-12-31 | 7.61% | AU$4.42 Million ≈ $3.13 Million |
AU$58.04 Million ≈ $41.07 Million |
-19.28pp |
| 2022-12-31 | 26.90% | AU$12.63 Million ≈ $8.94 Million |
AU$46.95 Million ≈ $33.22 Million |
+25.86pp |
| 2021-12-31 | 1.04% | AU$408.88K ≈ $289.31K |
AU$39.48 Million ≈ $27.93 Million |
+0.49pp |
| 2020-12-31 | 0.54% | AU$100.60K ≈ $71.18K |
AU$18.49 Million ≈ $13.08 Million |
+0.08pp |
| 2019-12-31 | 0.46% | AU$49.77K ≈ $35.22K |
AU$10.81 Million ≈ $7.65 Million |
-- |
| 2018-12-31 | 0.00% | AU$0.00 ≈ $0.00 |
AU$13.99 Million ≈ $9.90 Million |
-- |
About Microba Life Sciences Ltd
Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates in two segments, Testing Services and Supplements, and Research and Development. The company also develops pathology, therapeutics, and diagnostics services based on the huma… Read more